MEDtalk: What characterizes the group of patients with non-metastatic castration-resistant prostate cancer?

Best Practice Nordic | Kesä 2020 | ASCO20 Virtual |

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study describes what characterizes the group of patients with non-metastatic castration-resistant prostate cancer.